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Innovations in cancer immunotherapy over the past decade have reinvigorated the field,
which currently stands poised to transform treatment of certain important cancer types. While
recent discoveries in immunotherapy have occurred in an era of intense focus on precision
medicine—spurred in large part by advances in sequencing technologies allowing for unprece-
dented insights into individual and tumor genomes—the field of cancer immunotherapy is
rooted in a history that is anything but precise. The idea that the immune system could be
used to target cancer has existed for over a century. In the 1890s, William Coley provided a
spark by noting a connection between spontaneous tumor regressions and concurrent bacte-
rial infections [1]. Suspecting an immune mechanism, Coley and many others in the decades
that followed experimented with live bacteria, toxins, vaccines, and countless other agents to
coax the immune system to attack cancer, yielding only a tiny number of positive responses
and little understanding of the underlying immune mechanisms. As recently as 2010, immu-
notherapy remained a strikingly imprecise endeavor, with the only United States Food and
Drug Administration (FDA)-approved cancer immunotherapies being a pair of systemic cyto-
kines—interferon-α and interleukin-2—and intravesical bacillus Calmette-Gue´rin (BCG).
However, as recent successes reshape the field, efforts to comprehend and harness precise
mechanisms in immunotherapy will be required.
Breakthroughs in Melanoma
Perhaps the most profound impacts of both immunotherapy and precision medicine, in the
form of targeted therapy, can be appreciated in the transformation of treatment for metastatic
melanoma during the past decade. The discovery of the oncogenic V600E driver mutation in
BRAF, which is present in ~50% of melanomas, led to the development of vemurafenib and
dabrafenib, which are inhibitors of the mutant BRAF kinase [2]. Although targeting mutant
BRAF kinase and inhibiting the downstream mitogen-activated protein kinase (MAPK) path-
way produces high response rates in melanoma patients, the duration of responses is brief [3],
highlighting the need for additional therapies. Meanwhile, preclinical evidence suggested that
blocking negative regulators, or checkpoints, of T cell responses could improve antitumor
immune responses (Fig 1). The first such negative regulator tested was cytotoxic T-lympho-
cyte-associated protein 4 (CTLA-4), a T cell surface receptor that binds with high affinity to
the costimulatory ligands B7-1 and B7-2 found on the surface of antigen-presenting cells. The
interaction with CTLA-4 prevents binding of the costimulatory ligands to cluster of differenti-
ation 28 (CD28), a major costimulatory receptor on the T cell necessary for a robust T cell
response. Despite concerns about uncontrollable autoimmunity resulting from systemic
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CTLA-4 blockade, ipilimumab, a monoclonal antibody against CTLA-4, improved overall sur-
vival in patients with metastatic melanoma [4].
The successes of ipilimumab were quickly followed by trials targeting the immune inhibi-
tory interaction between programmed cell death protein 1 (PD-1), found on T cells, and its
ligand, PD-L1, found on tumor cells. In contrast to the central immune inhibitory effects of
CTLA-4, inhibition through PD-1 predominantly occurs at the periphery, with tumor cells
up-regulating PD-L1 in response to local immune signals such as interferon-γ. In a major
head-to-head clinical trial, pembrolizumab, a monoclonal antibody against PD-1, demon-
strated improved progression-free and overall survival with fewer high-grade adverse events
compared to ipilimumab [5]. Importantly, in a minority of cases, checkpoint inhibition pro-
duces strikingly durable responses, with up to a third of advanced melanoma patients alive at
five years of follow-up [6]. The majority, unfortunately, fail to respond to immunotherapy,
with objective response rates to checkpoint inhibitor monotherapy ranging from 10%–40%,
with PD-1/PD-L1 targeted antibodies benefiting larger proportions of patients [4,5,7]. Because
the mechanisms of CTLA-4 and PD-1 blockade are distinct and potentially complementary,
dual checkpoint blockade increases response rates to around 60%, albeit with significantly
more adverse events [8,9]. In a matter of a few years, immune checkpoint blockade has become
first-line therapy for advanced melanoma and transformed the outlook for patients. Looking
ahead, uncovering predictive markers of response to immunotherapy and ultimately under-
standing the mechanisms of response will be necessary to extend the promise of immunother-
apy to broader groups of cancer patients.
Fig 1. Central and peripheral immune checkpoints. Central immune inhibition occurs as a result of CTLA-
4 binding to the costimulatory B7 ligands found on antigen-presenting cells (APCs) with high affinity,
preventing signaling through CD28. Antibodies targeting CTLA-4 release this checkpoint to allow T cell
activation. Peripheral immune inhibition occurs through binding of the PD-L1 found on tumor cells to the PD-1
receptor on T cells. Antibodies targeting either the ligand or the receptor release this checkpoint.
doi:10.1371/journal.pmed.1002196.g001
PLOS Medicine | DOI:10.1371/journal.pmed.1002196 December 13, 2016 2 / 6
receptor; VEGF, vascular endothelial growth factor;
VEGFR, vascular endothelial growth factor
receptor.
Provenance: Commissioned; not externally peer-
reviewed
Efforts to uncover the precise mechanisms of immune checkpoint inhibition and identify
patients likely to benefit from treatment are well under way. Pathologists have long recognized
the prognostic significance of tumor-infiltrating lymphocytes [10], and, unsurprisingly, pre-
treatment CD8+ T cell density is associated with favorable response to immune checkpoint
blockade [11]. However, preclinical data suggest that CD8+ T cells in the tumor microenviron-
ment can promote immune inhibition as a result of interferon-γ-mediated induction of PD-L1
on tumor cells [12]. Response to anti-PD1 therapy in melanoma as well as other cancers has
been suggested to positively correlate with tumor expression of PD-L1 [13,14], highlighting
the central role of this ligand in tumor immune evasion, although PD-L1 expression thus far
appears to be an imperfect predictive biomarker of response. A comprehensive understanding
of immunotherapy requires a deeper analysis of the interaction between immune system and
tumor.
Genomics-Guided Advances
The rapid progress in cancer genomics in recent years has enabled a close examination of the
genetic makeup of thousands of individual cancers across the entire spectrum of major cancer
types. Amidst the search for mutations responsible for driving carcinogenesis, it has become
evident that overall mutation rates vary dramatically both within and between cancer types
[15]. While the vast majority of mutations contribute little, if at all, to intrinsic biological func-
tion in tumor development and survival, they represent novel, “non-self” epitopes that, if pro-
cessed and presented, carry the potential to elicit a tumor-specific immune response [16]. By
mining exome sequencing data to predict neoantigens present in a tumor, several groups have
demonstrated a strong correlation between total neoantigen burden and positive response to
immune checkpoint blockade [17,18]. These insights provide a mechanistic rationale to
expand checkpoint inhibition to mismatch repair-deficient cancers of any type, because the
dramatically elevated mutation rates in these cancers produce significantly more neoantigens
and the potential for a more robust immune response [19].
Although the importance of neoantigens is now firmly established, substantial overlap in
neoantigen burden exists between nonresponders and responders, highlighting the need to
more precisely identify the tumor-specific antigens required for a successful immune response.
Emerging evidence suggests that clonal neoantigens—that is, neoantigens present in all cancer
cells—rather than total neoantigen load are critical for T cell recognition and clinical benefit
from checkpoint blockade [20]. The critical neoantigens also need not be shared between
patients. One targeted approach with the potential to improve and increase responses to
checkpoint inhibition is to produce personalized vaccines specific to the neoantigens present
in a patient’s tumor [16,21].
However, selecting and manufacturing the optimal neoantigen vaccines within a clinically
meaningful time frame remains challenging, and successful targeting of tumor neoantigens
requires antigen-specific T cells, which may not be present. Indeed, the efficacy of CTLA-4
blockade likely stems in part from an expansion of the peripheral T cell receptor (TCR) reper-
toire [22], which presumably includes neoantigen-specific TCRs. Nascent experimental and
computational methods may help to resolve the critical TCR–antigen interactions in each
tumor [23,24], providing the critical blueprints for delivering precision immunotherapy.
As the precise mechanisms of immune checkpoint inhibition continue to be unraveled,
great interest has emerged in combining checkpoint blockade with current targeted therapies.
Substantial research on BRAF mutant melanoma indicates that BRAF inhibition synergizes
with immune checkpoint blockade by facilitating T cell recognition of melanoma antigens in a
more favorable tumor microenvironment [25,26]. Although one early trial combining
PLOS Medicine | DOI:10.1371/journal.pmed.1002196 December 13, 2016 3 / 6
immune checkpoint blockade with BRAF inhibition stalled because of hepatotoxicity [27],
many additional trials are ongoing to optimize dosing and sequencing of the combination. An
attractive feature of combining immune checkpoint blockade with targeted therapy is the
potential to leverage current advances in precision medicine to impact many cancer types. For
example, in BRCA1-deficient ovarian cancer, inhibition of poly(ADP-ribose) polymerases
(PARPs), a family of enzymes involved in DNA repair, markedly increases mutational load in
tumor cells and has demonstrated synergistic potential with CTLA-4 blockade [28]. Targeting
driver mutations such as those in the genes encoding c-KIT or epidermal growth factor recep-
tor (EGFR) with specific inhibitors appears to foster antitumor immunity [29,30]. In many
cancers, disrupting tumor angiogenesis by inhibiting vascular endothelial growth factor
(VEGF)/vascular endothelial growth factor receptor (VEGFR) promotes immune cell recruit-
ment and infiltration, which may derive additional benefit from checkpoint inhibition [31]. In
all of these cases and others, clinical trials are ongoing to determine the ability of targeted ther-
apies to potentiate response to immune checkpoint inhibition.
Future of Precision Immunotherapy
Propelled by recent successes, enthusiasm for immunotherapy has surged beyond targeting
CTLA-4 and PD-1 pathways. Many additional immune regulators, both stimulatory and
inhibitory, are being explored as potential targets for cancer immunotherapy, each with a
unique set of advantages and potential risks. Novel insights into neoantigens and combination
with immune checkpoint inhibition have breathed new life into cancer vaccines, which had
been tested for decades with little success. In addition, cell-based therapies may be required in
some patients to elicit a robust antitumor response. Adoptive cell transfer of autologous T cells
selected for tumor reactivity [32] and genetically engineered T cells with chimeric antigen
receptors targeting tumor antigens [33] have demonstrated promise in melanoma and other
cancer types. As new immunotherapies expand the arsenal of cancer therapies, deeper mecha-
nistic insight will be required to inform clinical decisions. The exciting advances toward
understanding and delivering precision immunotherapy are poised to change the way cancer
is treated.
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